A clinical formulation indicated for COVID-19. This medication supports the reduction of viral replication to mitigate the severity of symptoms and promote faster recovery periods.
An antiviral medication intended to manage COVID-19 symptoms and designed to alleviate risk of hospitalization by targeting viral replication to support recovery.
Mechanism of Action
It works by introducing errors into the genetic material of the virus during replication. This prevents the virus from producing viable copies, slowing the infection.
Route of Administration
Oral
Onset Time
5-day course
Duration
N/A
Contraindications
Pregnancy, Under age 18, Allergy to molnupiravir
Severe Adverse Events
Severe allergic reaction, Potential for mutation risk
Common Side Effects
Diarrhea, Nausea, Dizziness
Uncommon Side Effects
Headache, Fatigue
Pregnancy Safety Warnings
Not recommended; can cause fetal harm. Effective contraception required during and after treatment.
Information for Molnunat is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
